Our People
We draw on our diverse experience and global relationships
KHOO Shih, PhD
Chief Executive Officer
Read BioKhoo Shih has been instrumental in establishing ClavystBio. As Managing Director of Life Sciences Investments at Temasek, she was a key member of the founding team that conceived and formed ClavystBio.
Khoo Shih is passionate about accelerating innovations to transform human health. She has over 20 years of experience investing in private and public life sciences and healthcare companies globally. At Temasek, she successfully grew the life sciences portfolio and led biopharma and early-stage innovation investments and strategies.
Before joining Temasek, Khoo Shih was with UOB Venture Management where she was responsible for investing in life sciences venture and growth companies in China and USA. Her business career began in the Biomedical Sciences cluster at the Singapore Economic Development Board, as part of the team that spearheaded the growth of the biomedical industry in Singapore.
Khoo Shih holds a PhD in Genetics and Development from the University of Texas Southwestern Medical Center, USA and BSc in Microbiology from National University of Singapore. She currently serves on the Board of Directors of Cirrus Therapeutics, Nuevocor, and Paratus Sciences, and the Supervisory Board of Leyden Labs.
Kang Lin ONG, PhD
Chief Financial Officer
Read BioKang Lin brings over 20 years of experience in finance, investments and capital raising to ClavystBio, with a proven track record in Singapore, Hong Kong, China and Australia.
His recent roles include Group CFO of Luye Medical Group, a major private healthcare services provider in the Asia Pacific, and CFO of Docquity, one of Southeast Asia's largest digital platforms for healthcare professionals.
Kang Lin has also held board positions in companies spanning the real estate, asset management, manufacturing, and biopharma industries, across both publicly listed and private entities.
Kang Lin holds a PhD in Finance from EDHEC Business School, France, an MBA from The Wharton School, University of Pennsylvania, where he was a Palmer Scholar, and BBA (Hons) from the National University of Singapore. He is also a CFA Charterholder.
Venture Building & Investing
Wen Qi HO, PhD
Therapeutics Lead
Read BioWen Qi focuses on investing in and building global healthcare companies from Singapore. Prior to joining ClavystBio, she headed up the Singapore investments and operations for Lightstone Ventures, where she played a major role in establishing the firm’s presence in Singapore. Wen Qi evaluated new investment opportunities in the biopharmaceutical and medical device sectors and was actively involved in venture-building, working closely with companies in their development journey.
Wen Qi is an advocate for early-career researcher participation in biotech entrepreneurship, and serves on advisory and grant review panels with leading institutions in Singapore. She also serves on the Board of Directors of Automera, Engine Biosciences, MediSix Therapeutics, and the steering committee of 65LAB.
Wen Qi holds a PhD in Immunology at Stanford University, and BSc in Molecular and Cellular Biology at Johns Hopkins University.
Anselm TAN
MedTech Lead
Read BioAnselm oversees digital health and medtech ventures at ClavystBio. He is actively involved in the startup ecosystem for healthcare innovations in Singapore, where he serves on evaluation panels and advises the Singapore Deep Tech Alliance.
Anselm has extensive experience across private and corporate venture capital. He was Managing Director and Head of Venture Capital at Heritas Capital, which manages investments in healthcare, education and technology, and Partner at Philips Ventures, where he launched and led health technology investments in APAC. Prior to this, Anselm served in various roles at Standard Chartered, including in the establishment and management of funds, risk management, and finance. He started his career as an engineer at the Defence Science & Technology Agency.
Anselm holds a BEng in Electrical & Electronic Engineering from Nanyang Technological University, Singapore, and is a Fellow Chartered and Certified Accountant.
Yvonne KOH, PhD
Director, Therapeutics
Read BioYvonne brings a unique blend of commercial and public sector experience to investing and venture building at ClavystBio. Her multi-faceted career includes roles in venture capital investing, business strategy, product development, technology commercialization, and innovation policy across the biotech and medtech sectors.
Yvonne was previously at Lightstone Ventures (LSV) and was involved in due diligence and program management for the firm’s early-stage ventures globally and in Singapore. Prior to that, Yvonne was Deputy Director at the National Research Foundation where she led the development and implementation of Singapore’s innovation strategy. She has also held operational roles at a Singapore-based medical diagnostics start-up.
Yvonne holds a PhD in Biochemistry from the University of Wisconsin Madison, USA, and BSc in Molecular Biology from the University of Illinois Urbana-Champaign, USA.
Yingmin WANG, PhD
Director, MedTech
Read BioYingmin is fascinated by the intersection of science, business and social impact, a passion which fuels her work in investment and venture building at ClavystBio.
Yingmin’s experience spans R&D, ventures and operations in hi-tech sectors such as life sciences, agrifood and semiconductors. She started her career as a research scientist at A*STAR before transitioning into business roles, first in new business development and new ventures at the Singapore Economic Development Board and most recently at Applied Materials where she led the Southeast Asia Regional Office and CTO’s satellite office in Singapore as Chief of Staff to the Regional President.
Yingmin holds a PhD in Biomedical Eengineering from the California Institute of Technology, USA, and BSc in Biomedical Engineering from Duke University, USA.
Johnny NG, PhD
Assistant Vice President, Therapeutics
Read BioJohnny believes that improving treatment options for patients and delivering returns for shareholders should go hand in hand. He is passionate about the translation and commercialisation of life science research in Singapore.
Johnny’s experience spans both the private and public sectors. He was previously at Xora Innovation where he shaped the life science portfolio, managed end-to-end deal flow and served as a board observer in several companies. Prior to that, Johnny led a discovery program at Experimental Drug Development Centre (Singapore’s national platform for drug discovery and development) that was outlicensed to a top 20 pharma company, while supporting business development. He also contributed to value creation at an early-stage biotech spun out of his advisor's lab.
Johnny holds a PhD in Biomedical Engineering from Columbia University and BSc in Chemical Engineering (summa cum laude) from the University of Illinois Urbana-Champaign.
Cheryl TAN, MD
Assistant Vice President, MedTech
Read BioCheryl is passionate about bridging the gap between medicine and life sciences investing, bringing distinctive medical insight into the investment process. Having spent more than a decade in the medical industry, Cheryl leverages her medical expertise to identify and evaluate impactful investment opportunities in the healthcare sector. Her unique blend of clinical experience and investment acumen allows her to assess innovations from both a medical and financial perspective, ensuring that investments align with patient needs and clinical realities.
Cheryl was previously part of the Temasek Life Sciences team where her investing experience spanned all healthcare verticals from tools and diagnostics to therapeutics, as well as both public and private sectors. Prior to that, Cheryl practiced medicine in Australia, training in general surgery.
Cheryl holds an M.D. from the University of New South Wales, Sydney Australia.
Charles Yiliu ZHANG, PhD
Assistant Vice President, Therapeutics
Read BioCharles is energized by the accelerating pace of innovation in biomedical research, and the potential of fledgling startups to create life changing medicines and devices. At ClavystBio, he draws upon his diverse background in science, intellectual property (IP), and venture investment to help scientists and start-ups create lasting impact for patients across the world.
Charles started his career as a post-doctoral research scientist at the Institute of Cell & Molecular Biology (IMCB), A*STAR and later worked as a trainee patent attorney at an international firm. Before joining ClavystBio, Charles was in a Singapore based biotech VC focusing on venture creation and investment.
Charles attained his PhD in Cell and Molecular Biology from the National University of Singapore (NUS), and BSc in Life Science from Sun Yat-sen University, China. He also holds a Graduate Certificate in IP from the Faculty of Law, NUS and IP Academy Singapore.
Ning MAO, PhD
Senior Associate
Read BioNing is passionate about the business of science, and in particular the process of translating scientific research into exciting companies. She channels this passion into investment and venture creation work at ClavystBio to help realize the commercial value and medical benefits of life sciences innovations in Singapore.
Before joining ClavystBio, Ning worked at a venture firm focusing on early-stage biotech investments. She worked closely with portfolio companies and gained biotech operations and business development experience. Prior to that, she was a consultant advising clients in the life sciences industry on commercial strategy.
Ning holds a PhD in Biomedical Engineering from Boston University, USA, and BSc in Bioengineering from Nanyang Technological University, Singapore.
Marcus TAN, PhD
Senior Associate
Read BioMarcus believes that advancing patient care and creating stakeholder value should move in tandem. At ClavystBio, he channels this belief into venture creation and investment, building globally relevant companies with founders, researchers and industry partners.
He brings over a decade of experience across venture capital, biotech, and translational research. At Danaher Corporation, he managed venture efforts in genomic medicine, bioprocessing and diagnostics across Asia. Prior to that, he was with Heritas Capital, where he focused on investment opportunities across healthcare, food, education and sustainability sectors. He also was at Advanced MedTech, Lerna Biopharma and A*STAR where he oversaw diagnostics commercialization, business operations and R&D, respectively.
Marcus holds a PhD in Biomedical Sciences (Virology) from Harvard University and a BSc in Biochemistry from the University of Wisconsin–Madison, graduating with Highest Distinction and Honors in Research. He also holds the Graduate Certificate in IP Law from the National University of Singapore.
Corporate Development
Carol CHAN
Executive Assistant and Office Manager
Read BioCarol Chan supports ClavystBio’s C-suite leaders, managing executive schedules and office operations. She has over a decade of experience in high-level administrative roles with leading executive search and consultancy firms including Eric Salmon & Partners and DTCA - Executive Search Partners in Asia.
Carol holds LCCI Secretarial qualifications from Thames Business School.
Grace CHUA
Community Engagement Manager
Read BioGrace manages ClavystBio’s events, facilitating thought leadership discussions and networking across the life sciences ecosystem. Passionate about bringing diverse stakeholders together to create impactful connections, she says,“ I am driven by building a vibrant community that collaborates to drive innovation and health impact.”
Prior to joining ClavystBio, Grace was an Assistant Manager at Singapore’s National Environment Agency (NEA), where she spearheaded programmes and partnerships with Institutes of Higher Learning and youth segments. She played a pivotal role in conceptualizing and implementing NEA’s flagship youth environmental programme.
Grace holds a BSc in Sociology with Honors (Distinction) from Nanyang Technological University, Singapore.
Vincent LAI
Vice President, Cybersecurity & IT
Read BioVincent leads ClavystBio’s cybersecurity and IT strategies, ensuring robust data governance and secure digital infrastructure to protect sensitive data and support impactful collaborations across ClavystBio's partnerships. A seasoned professional in IT, cybersecurity, and data privacy, Vincent excels in forging collaborations across technical and business domains, addressing regulatory challenges, and aligning cybersecurity strategies with ClavystBio’s business objectives.
With over 15 years of experience in designing and implementing secure, scalable IT frameworks, Vincent has driven IT governance, regulatory compliance, risk management, and operational excellence across sectors including e-commerce and logistics. Combining expertise in IT, cybersecurity, and data privacy with a business-driven approach,
Vincent delivers secure, effective solutions that empower innovation and growth. Vincent holds a B.Comp from the National University of Singapore, complemented by professional certifications in cybersecurity and data privacy that underscore his commitment to advancing excellence in IT and cybersecurity.
Jason NG
Legal Lead
Read BioJason oversees the legal facets of ClavystBio’s venture building efforts, combining deep legal expertise with entrepreneurial insight. He brings nearly 20 years of progressive legal experience, with over a decade dedicated to the startup ecosystem. With a career spanning the public (within the Ministry of Law), private, and social sectors, he offers a rare tri-sector perspective.
At ClavystBio, Jason has played a key role in multiple investments into both venture funds and start-ups, from seed to Series D, including an M&A exit and over US$1 billion in value creation. He previously served as General Counsel at a biotech start-up, where he led its largest fundraise and executed a strategic carve-out. He was also General Counsel at a deep tech start-up, where he initiated a turnaround into operational profitability and implemented a channel partner strategy that drove hyper-growth across three regions.
Jason holds a BA in Jurisprudence from Oxford University, UK, and an MBA from INSEAD, France. He is also a Kellogg School of Management alumnus (USA exchange program).
Nge Hwee NG
Business Development & Operations Lead
Read BioNge Hwee drives Business Development and Operations at ClavystBio, and looks at improving connectivity and collaboration among players within the life sciences ecosystem. A founding member of the team, she is energised by the zero-to-one environment of setting up a new company, and the potential impact of ClavystBio’s work.
Nge Hwee was most recently Vice President (Portfolio Development Group) at Temasek, where she worked since 2014. Prior to Temasek, Nge Hwee was with the Corporate Finance and Valuations teams at PricewaterhouseCoopers.
Nge Hwee holds a double degree in Business and Accountancy (First Class Honours) from Nanyang Technological University, Singapore.
Regis ONG
Infrastructure Lead
Read BioRegis is overseeing the development of ClavystBio’s lab facility and infrastructure at Science Park. A champion for co-working labs, he sees them as the solution to the huge gap between spin-offs and manufacturing that many scientists fail to overcome. “They solve the primary problem of the sheer expense of building a lab, and allow scientists to do what they do best – bump heads and collaborate to generate new ideas.”
Prior to joining ClavystBio, Regis was Technical Head for Fuchs Singapore and a founding team member of Life Science Incubator. He also has extensive experience managing quality control for leading pharma MNCs.
Regis holds a Bsc in Biomedical Sciences from the University of Bradford, UK.
Ewen POH
Human Resources Manager
Read BioEwen drives the HR functions at ClavystBio, managing HR operations, talent management and talent acquisition. She is passionate about fostering strong partnerships and delivering impactful HR solutions.
Prior to joining ClavystBio, Ewen served as an HR Business Partner at leading early-stage biotech firms in Singapore where she successfully managed HR operations across Singapore and the regions. She spearheaded HR improvement projects and played a key role in organizational restructuring efforts. Her earlier experience as a Recruitment Consultant in Executive Search firms further refined her expertise in identifying and recruiting top-tier talent for the healthcare and life sciences industries.
Ewen holds a BSc in Biological Sciences from Nanyang Technological University, Singapore.
Jamie WONG
Director, Finance
Read BioJamie oversees the financial functions at ClavystBio, establishing an efficient system backed by robust governance and compliance principles. She also works closely with ClavystBio’s portfolio companies to provide insights and support them in building strong financial foundations to enable their businesses to thrive.
Jamie is passionate about being part of an organization focused on improving patients’ lives around the world, and brings over 20 years of finance management experience. She was previously Director (Finance) at Temasek International where she held responsibilities over the years in corporate accounting and reporting, international office finance, consolidation, management reporting and budgeting. Additionally, Jamie built the finance functions of Temasek’s international offices in 8 countries and 12 locations, and led the Finance and Business Transformation project to implement Workday across the globe. Prior to Temasek, Jamie was an Audit Senior at KPMG handling Japanese multinational corporations, Singapore listed companies, and IPO listings.
Jamie is a Chartered Accountant, and holds a BAcc from Nanyang Technological University, Singapore.
Gladys YEO
Infrastructure Manager
Read BioGladys manages ClavystBio’s collaboration space, Node 1, ensuring the smooth running of the laboratories and offices and supporting current and new tenants.
With over a decade of experience in diagnostic laboratory operations, she views her work here as a fresh challenge, sharing “It’s exciting to be in a startup environment, where the focus is on R&D. It keeps me in touch with the latest advancements in technology.”
Gladys holds a BSc in Biomedical Science from Aston University, UK.
Samantha YEO
Manager, Finance & Compliance
Read BioSamantha supports ClavystBio on finance and compliance matters. She believes that finance is a powerful tool in ensuring company growth and ongoing success.
Samantha started her career in the Governance, Risk and Advisory team at KPMG, gaining experience in enterprise risk management, compliance review and internal audit reviews in Singapore and overseas. She then joined Lightstone Ventures, where she focused on setting up and supporting the smooth running of finance functions and operations in early-stage life science ventures.
Samantha holds a BAcc with a second major in Finance from Singapore Management University.
Ken EHLERT
Director
Read BioKen spent the early years of his career working across the industries of agriculture, finance, and retail, before finding a home in healthcare. Since then, he has focused on using data, analytics, and a longitudinal understanding of disease to build products and businesses that improve the healthcare system. His career spans three decades and consists of numerous leadership positions and entrepreneurial endeavors, including serving as UnitedHealth Group’s Chief Scientific Officer.
Ken has founded and successfully exited several companies, including All Savers—a novel insurance product for small businesses that brings the advantages of large groups, Motion—the first pay[1]for-healthy-behaviors insurance program that used biosensors, Level2—the first insurance plan that combines disease-specific interventions with benefit design, and Savvysherpa—a healthcare R&D firm focused at the intersection of math, clinical science, and human connection.
Today, Ken is most passionate about the linkage between cognition, behavior, biology, and chronic diseases. His efforts are aimed at exploring this linkage and harnessing it to improve health and access to healthcare, especially for those who are socio-economically challenged.
KHOO Shih, PhD
Chief Executive Officer
Read BioKhoo Shih has been instrumental in establishing ClavystBio. As Managing Director of Life Sciences Investments at Temasek, she was a key member of the founding team that conceived and set up the company.
Khoo Shih is passionate about accelerating innovations to transform human health. She has over 20 years of experience investing in private and public life sciences and healthcare companies globally. At Temasek, she successfully grew the life sciences portfolio and led biopharma and early-stage innovation investments and strategies.
Before joining Temasek, Khoo Shih was with UOB Venture Management where she was responsible for investing in life sciences venture and growth companies in China and USA. Her business career began in the Biomedical Sciences cluster at the Singapore Economic Development Board, as part of the team that spearheaded the growth of the biomedical industry in Singapore.
Khoo Shih holds a PhD in Genetics and Development from the University of Texas Southwestern Medical Center, USA and BSc in Microbiology from National University of Singapore. She currently serves on the Board of Directors of Cirrus Therapeutics, Nuevocor, and Paratus Sciences, and the Supervisory Board of Leyden Labs.
Ranga KRISHNAN
Director
Read BioDr Ranga Krishnan is Senior Advisor to the Rush University System for Health in Chicago. He was previously Dean of Rush Medical College, and Chief Executive Officer of the Rush University System for Health. Ranga advanced the innovation of care delivery by organising providers around patients, diseases and conditions rather than by department or division to enable greater multidisciplinary collaboration. He also remodelled Rush’s innovation and technology strategy, including the Innovation and Technology Transfer Office which manages Rush’s intellectual properties.
Prior to Rush, Ranga was Dean of Duke-NUS Graduate Medical School Singapore, where he developed a teaching method called Team LEAD (Learn, Engage, Apply, Develop) which has since been adopted by other universities and high schools.
Ranga is a member on Singapore's Research, Innovation and Enterprise Council (RIEC) Human Health and Potential International Advisory Committee. He also previously served as Chairman of the National Medical Research Council (NMRC) in Singapore.
Steve KROGNES
Director
Read BioSteve Krognes is a professional board member in the biotech and life science sector. He currently serves as a Director at Denali Therapeutics, Guardant Health, Gritstone bio and argenx, all publicly listed companies, and previously served on the boards of Corvus Pharmaceuticals, RLS Global AB and Tessa Therapeutics.
Previously, Steve worked 7 years as CFO of Denali Therapeutics, 6 years as CFO of Genentech and 6 years as global head of M&A at Roche. At Denali, Steve built the finance, IT and site organizations, and led the company’s IPO and capital raising efforts. At Genentech, Steve led the integration of InterMune as well as the integration of Roche and Genentech, chaired the Genentech Access to Care Foundation and represented Genentech on the Board and Executive Committee of the California Life Science Association. At Roche, under Steve’s leadership, the M&A team executed more than 30 transactions worldwide, and he personally led the acquisition of and subsequent integration of Genentech.
Prior to that, Steve worked as an investment banker at Goldman Sachs, a management consultant at McKinsey, and as a venture capitalist in Scandinavia. Steve holds an M.B.A. from Harvard Business School, a B.S. in Economics from the Wharton School of the University of Pennsylvania. Steve grew up in Norway and is a second lieutenant in the Royal Norwegian Air Force, and speaks Norwegian, French, and conversational German. Steve lives in Cannes (France) and San Francisco (USA) with his family.
Ethan PARK
Director
Read BioEthan Jung Ryun Park is a Managing Director of the Asia Pacific (ex China and India) team at Temasek. Prior to his current role, Ethan leads the firm’s healthcare & life sciences investment activities in Europe, Middle East and Africa (EMEA), and Southeast Asia (SEA). Previously, he was with SK Corporation in Seoul, Korea.
Ethan holds a BA from Tufts University, where he was a member of Phi Beta Kappa and graduated magna cum laude. He also holds an MS from the London School of Economics and Political Science, and has received an international diploma from the Institut d’Etudes Politiques de Paris (Sciences Po).
He serves on the boards of several healthcare and life sciences companies.
Vicki SATO
Director
Read BioDr Vicki Sato is a Venture Partner at ARCH Venture Partners, Chairman of Vir Biotechnology and Denali Therapeutics, and a business advisor to several enterprises in the biotechnology and pharmaceutical industries.
Vicki was previously a Professor of Management Practice at Harvard Business School and a Professor of the Practice, Molecular and Cell Biology, for Harvard’s Faculty of Arts and Sciences. Prior to that, Vicki spent many years in the industry, including most recently as President of Vertex Pharmaceuticals.
Vicki is a member of the President’s Council of Advisors on Science and Technology (PCAST) in the United States, and was the inaugural Co-Chair of the Advisory Council for the NYC LifeScience Initiative to establish New York City as a global leader in life sciences.
Andrew CLEELAND
Advisor
Read BioAndrew Cleeland is CEO of Fogarty Innovation, a non-profit medtech incubator based in Silicon Valley. He is a seasoned executive with over 30 years of leadership experience in the medical device industry across the private and public sectors.
Prior to joining Fogarty, Andrew led Medtronic’s Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was CEO. Prior to Twelve, he was CEO of Ardian Inc. which was acquired by Medtronic in 2011. He currently serves on the boards of five companies: Saluda Medical, Zenflow Inc. (chairman), MMI Inc. (chairman), Francis Medical (chairman) and atHeart Medical. He also holds advisory positions at Longitude Capital, Arboretum Ventures and EQT Private Equity, and has been invited to serve on the UCSF-Stanford Pediatric Device Consortium; the board of MDIC; and Singapore’s Medtech Catapult.
Sean MARETT
Advisor
Read BioSean Marett was a member of the management board of BioNTech from 2012 to 2024. In his 12 years on the board, he played a significant role in the company’s growth and global expansion through leading fundraising, business development and product commercialization activities which generated over $22 billion in cash for BioNTech to June 2024.
Earlier in his career, he worked in commercial roles in Pfizer and GSK in Europe and in the USA as well as working for European biotech, manufacturing and research service companies.
He is also currently non-executive director of the biotechnology company AiCuris AG. Previously, he was non-executive director of Bambusa Therapeutics Inc, KWS Biotest Ltd and PHMR Ltd, the latter two of which he helped to exit through trade sales.
He has been honored with a number of awards and recognitions, including the Companion of the Most Distinguished Order of St Michael and St George awarded by Her Majesty Queen Elizabeth II, the then monarch of the United Kingdom.
He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School in the UK.
Andreas WALLNÖFER
Advisor
Read BioAndreas Wallnöefer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team and nearly a decade as a board member in several biotech companies. He has been a Partner at the Swiss venture capital firm BioMedPartners and later at Jeito Capital, a leading European investment company based in Paris.
An accomplished investor, board member and operator, Andreas has played a pivotal role in developing many innovative companies, contributing to several successful exits, including the recent acquisition of EyeBio by MSD—a deal valued in total at US $3 billion, achieved only 3 years after the company’s inception.
Prior to his career in venture capital, he was Head of Cardiovascular and Metabolism (CVM) R&D at Roche and a member of the Roche/Genentech Portfolio Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech (now a wholly owned member of The Roche Group), Andreas was Global Head of Clinical Research and Exploratory Development and led the R&D organization at multiple sites in Europe, the U.S., and Asia. He had a key role in the integration of the Roche and Genentech development organizations and subsequently led Roche’s Early Development Department.
From 2009 to 2013, Andreas chaired the collaboration between Roche and Singapore Research institutes and since, has been deeply involved in progressing Singapore’s biotech ecosystem.
Andreas holds a Ph.D. in Pharmacology from the University of Basel, degrees in Pharmaceutical Medicine, and was trained as a Clinical Research fellow at the Centre of Human Drug Research at the University Hospital of Leiden, Netherlands. He also holds an Executive M.B.A. from IMD Lausanne.